SCHEMBL7531263

SCHEMBL7531263

COc1ccc(-c2cn(CC(=O)O)c3cc(OC)ccc3c2=O)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 1/20 0.45
AKR1A1 P14550 1/20 0.45
AKR1B1 P15121 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.44
KDM4E B2RXH2 2/20 0.44
ALDH1A1 P00352 2/20 0.44
HPGD P15428 2/20 0.44
HSD17B10 Q99714 2/20 0.44
TSHR P16473 1/20 0.44
RAB9A P51151 1/20 0.44
GFER P55789 1/20 0.43
PTGDR2 Q9Y5Y4 1/20 0.42
XDH P47989 1/20 0.42
MEN1 O00255 1/20 0.42
TP53 P04637 1/20 0.42
CYP3A4 P08684 1/20 0.42
BCL2 P10415 1/20 0.42
CYP2D6 P10635 1/20 0.42
MAPT P10636 1/20 0.42
CYP2C9 P11712 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1924231 0.92 PTGDR2 (0.44) PTGS2AKR1B1SMN1; SMN2KDM4EALDH1A1
SCHEMBL7537499 0.88 CASP3 (0.50) SMN1; SMN2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL7262276 0.86 PDE4B (0.51) KDM4EALDH1A1HPGDHSD17B10TSHR
SCHEMBL7261269 0.85 TSPO (0.50) SMN1; SMN2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL2433501 0.85 ALDH1A1 (0.50) SMN1; SMN2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL7252752 0.82 ALDH1A1 (0.64) AKR1A1AKR1B1SMN1; SMN2KDM4EALDH1A1
SCHEMBL7532023 0.82 EGFR (0.48) PTGS2SMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL1925179 0.81 EGFR (0.48) SMN1; SMN2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL1924541 0.81 KDM4E (0.46) AKR1A1AKR1B1KDM4EALDH1A1RAB9A
SCHEMBL7257618 0.81 DYRK1A (0.41) SMN1; SMN2KDM4EALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1202971-A2 PHARMACEUTICAL COMPOSITIONS COMPRISING 4-QUINOLONES LABORATOIRE L. LAFON (FR) 2002-05-08 EP disclosed
WO-2002022074-A2 USE OF 2- AND 4- QUINOLONES FOR INHIBITING INTIMAL NEO-PROLIFERATION LABORATOIRE L. LAFON (FR) 2002-03-21 WO disclosed
WO-2001012607-A2 PHARMACEUTICAL COMPOSITIONS COMPRISING 4-QUINOLONES FOR TREATING CANCERS LABORATOIRE L. LAFON (FR) 2001-02-22 WO disclosed